On February 10, 2017, Santhera Pharmaceuticals Holding AG (Santhera) announced the successful placement of a CHF 60 m 5% senior unsecured convertible bond due 2022. Santhera is a Swiss specialty pharmaceutical company focused on medicines to treat mitochondrial disorders and other rare diseases. The convertible bond will be Santhera's first listed debt instrument and is expected to be listed on the SIX Swiss Exchange. Bank am Bellevue and Kepler Cheuvreux acted as joint lead managers.

Homburger acted as legal and tax counsel to Santhera. The Homburger team is led by partner Dieter Gericke (Corporate | M&A) and comprises partners Dieter Grünblatt and Stefan Oesterhelt (both Tax), counsel Eduard de Zordi (Financial Services), associates Daniel Häusermann and Marc Hanslin as well as junior associate Carlo Sulser (all Corporate | M&A).